Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
5.31
-0.21 (-3.80%)
At close: Feb 27, 2026, 4:00 PM EST
5.14
-0.17 (-3.20%)
After-hours: Feb 27, 2026, 7:59 PM EST
Larimar Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Larimar Therapeutics stock have an average target of 16.14, with a low estimate of 7.00 and a high estimate of 26. The average target predicts an increase of 203.95% from the current stock price of 5.31.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Larimar Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +163.65% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +107.16% | Feb 25, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $26 → $21 | Buy | Maintains | $26 → $21 | +295.48% | Oct 2, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $11 | Buy | Maintains | $15 → $11 | +107.16% | Sep 30, 2025 |
| Baird | Baird | Buy Maintains $10 → $7 | Buy | Maintains | $10 → $7 | +31.83% | Sep 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
2.07M
EPS This Year
-1.99
from -1.32
EPS Next Year
-1.85
from -1.99
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 17.0M | ||||
| Avg | n/a | 2.1M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.62 | -1.14 | ||||
| Avg | -1.99 | -1.85 | ||||
| Low | -2.14 | -2.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.